Ex.50.T Aptamer Impairs Tumor-Stroma Cross-Talk in Breast Cancer by Targeting Gremlin-1

Scientists highlighted ex.50.T as a novel therapeutical avenue for breast cancer and potentially other gremlin-1-dependent malignancies, offering insights into disrupting tumor microenvironment dynamics and enhancing cancer treatment strategies.